3 models fit SCHOTT Pharma AG & Co. KGaA and they disagree: 0 of 3 land within 15% of the average.
Two or more of our models back this value.
Large premium(i)Bronze54
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, Graham number, and Dividend discount.
ACCE opinionSCHOTT Pharma AG & Co. KGaA (1SXP.DE)
Fair value (3 models)
€17.19
ACCE price target
€27.30
Rating
Overvalued
Horizon
12 months
Fair value published on 22 Oct 2026, 13:04 CEST.
ACCE price target published on 23 Oct 2026, 01:53 CEST.
Rating published on 22 Oct 2026, 13:04 CEST.
Price used: €25.70 at the close on 23 Oct 2026, 17:30 CEST.
Models: Discounted cash flow, P/E comparison, and Graham number.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
49.5% above
-33.1% to fair value
ACCE score
61
out of 100
P/E
28.6x
forward 23.5x
1-year return
+26.9%
Dividend yield
0.70%
SCHOTT Pharma AG & Co. KGaA in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
SCHOTT Pharma makes glass primary packaging for injectables: prefilled syringes, vials, and cartridges for biologics and GLP-1 drugs, plus its Schott Pharma Plastics and Schott Pharma Drug Delivery lines. The moat is qualification: pharma customers validate a container alongside the drug it holds, so switching suppliers means years of stability testing, which keeps share sticky and pricing power intact. Revenue growth of 10.0% and a 17.4% operating margin reflect demand from the biologics and GLP-1 injectable boom flowing through to the packaging layer. The stock trades at 23.4x forward earnings against 28.4x trailing, implying the market expects earnings to rise meaningfully over the next year, so the question for a PM is whether that margin and volume trajectory holds as competitors like Gerresheimer and Stevanato add capacity. With a 3.8B EUR market cap and no index membership, the name is small enough that a concentrated position could move it, which warrants a closer look at capacity utilisation and order backlog before sizing.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
moderate
Earnings falling despite growth
Revenue grew 10.0% year on year, but earnings fell 13.3%, so margins or costs are moving against the top line. Worth checking the cause before reading the growth as clean.
moderate
Price well above model fair value
The stock trades 49.5% above the model fair value of €17.19, and the forward P/E of 21.6 is still rich relative to the 13.0 EV/EBITDA. Valuation leaves little margin for an earnings miss.
moderate
Thin float, concentrated ownership
Insiders hold 77.0% of the shares and institutions 20.1%, leaving a small free float. Liquidity can be poor and price moves sharper than the fundamentals alone would suggest.
AI research notes
AI-assisted·How I use AIWritten Oct 22, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Revenue grew 10.0% over the past year, close to its 11.0% average annual pace over five years.
Returns look healthy, with a 13.4% net margin, 14.7% return on equity and 13.5% return on invested capital.
The company generated EUR 35M of free cash flow over the last twelve months while holding its diluted share count flat.
Why it could disappoint
At EUR 26.00 the shares trade 49.5% above the model fair value of €17.19.
The free cash flow yield is only 0.9%, so the stock offers little cash return at this price.
The analysts' mean price target of EUR 24.92 sits 4.2% below the share price, suggesting limited upside to their view.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Dec 10, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where 1SXP.DE's valuation models land
Price
€25.70
Model fair value
€17.19
Model range
€11.43 to €27.58
Fair value €17.19
Price €25.70
The price sits inside the model range.
Model
Fair value
Upside
Discounted cash flow
Dividend discount
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores
+Score history: how each score moved over time
Analysts
Wall Street consensus
No analyst coverage yet.
Analyst intelligence INVESTOR FEATURE
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
+Price-target low / average / high vs the current price, with implied upside
+Forward revenue and EPS consensus by fiscal year
+ACCE fair-value models lined up against the Street
Smart Money
PRO
In one line
Trades are only made public after a delay. We show the delay so you know how old the news is.